VolitionRx Limited

Equities

VNRX

US9286611077

Biotechnology & Medical Research

Market Closed - Nyse Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
0.9137 ^USD	+2.65%		+48.33%	+27.43%

Apr. 26	VolitionRx Limited Announces Board Changes	CI
Apr. 23	VolitionRx Limited Launches In-Clinic in U.S. and Europe Through Antech	CI

VolitionRx Limited Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023

November 14, 2023 at 04:22 pm EST

VolitionRx Limited reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported revenue was USD 0.165211 million compared to USD 0.032714 million a year ago. Net loss was USD 8.37 million compared to USD 7.74 million a year ago. Basic loss per share from continuing operations was USD 0.11 compared to USD 0.14 a year ago. Diluted loss per share from continuing operations was USD 0.11 compared to USD 0.14 a year ago.
For the nine months, revenue was USD 0.531329 million compared to USD 0.186677 million a year ago. Net loss was USD 26.62 million compared to USD 23.03 million a year ago. Basic loss per share from continuing operations was USD 0.39 compared to USD 0.42 a year ago. Diluted loss per share from continuing operations was USD 0.39 compared to USD 0.42 a year ago.

Latest news about VolitionRx Limited

VolitionRx Limited Announces Board Changes	Apr. 26	CI
VolitionRx Limited Launches In-Clinic in U.S. and Europe Through Antech	Apr. 23	CI
Transcript : VolitionRx Limited, Q4 2023 Earnings Call, Mar 26, 2024	Mar. 26
VolitionRx Limited announced that it has received $0.1 million in funding	Mar. 25	CI
VolitionRx Limited Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 25	CI
North American Morning Briefing : Tech in Focus on -2-	Mar. 25	DJ
VolitionRx Limited Agrees Supply Agreement with Fujifilm Vet Systems Co. Ltd	Mar. 20	CI
VolitionRx Names Andrew Retter as Chief Medical Officer	Mar. 19	MT
Volitionrx Limited Appoints Andrew Retter as Chief Medical Officer, Effective April 1, 2024	Mar. 19	CI
VolitionRx Limited announced that it expects to receive $0.1 million in funding	Mar. 11	CI
Transcript : VolitionRx Limited - Special Call	Feb. 13
Sector Update: Health Care Stocks Gain Late Afternoon	Jan. 02	MT
Sector Update: Health Care	Jan. 02	MT
VolitionRX Shares Soar After $13.0 Million Milestone Payments From Heska	Jan. 02	MT
VolitionRx Limited Secures Approximately $5.5 Million in Belgium Regional Government Financing from Wallonie Entreprendre	Dec. 05	CI
VolitionRx Limited announced that it has received ?2.5 million in funding	Dec. 04	CI
Cantor Fitzgerald Adjusts Price Target on VolitionRX to $2.50 From $2.10, Maintains Overweight Rating	Nov. 16	MT
Transcript : VolitionRx Limited, Q3 2023 Earnings Call, Nov 15, 2023	Nov. 15
VolitionRx Limited Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
VolitionRx Limited and Veterinary Pathology Group joins forces to launch the Nu.Q(R) Vet Cancer Test to veterinary practices in the UK and Ireland	Nov. 06	CI
Transcript : VolitionRx Limited - Special Call	23-10-26
VolitionRx Limited Presents Breakthrough Liquid Biopsy Blood Test Method for Early-Stage Cancer	23-10-23	CI
Certain Options of VolitionRx Limited are subject to a Lock-Up Agreement Ending on 30-AUG-2023.	23-08-29	CI
Certain Restricted Stock Units of VolitionRx Limited are subject to a Lock-Up Agreement Ending on 30-AUG-2023.	23-08-29	CI
Certain Warrants of VolitionRx Limited are subject to a Lock-Up Agreement Ending on 30-AUG-2023.	23-08-29	CI

Chart VolitionRx Limited

Duration

Period

More charts

Company Profile

VolitionRx Limited is a multi-national epigenetics company focused on advancing the science of epigenetics. The Company is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring. Through its subsidiaries, it is developing and commercializing blood tests to help diagnose and monitor a range of diseases, including cancers and diseases associated with NETosis, such as sepsis. Its key pillars are Nu.Q Vet, Nu.Q NETs, Nu.Q Discover, Nu.Q Cancer and Capture-PCR. The Nu.Q Vet Cancer Test is commercially available as a cancer screening test in dogs. Nu.Q NETs is monitoring the immune system to save lives. Nu.Q Discover is a complete solution to profiling nucleosomes. Nu.Q Cancer monitoring disease progression, response to treatment and minimal residual disease. Capture-PCRTM is isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection.

Sector

Biotechnology & Medical Research

Calendar

2024-05-07 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for VolitionRx Limited

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.9137 USD

Average target price

3.725 USD

Spread / Average Target

+307.68%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Diagnostics & Testing

	1st Jan change	Capi.
VOLITIONRX LIMITED	+27.43%	74.99M
EXACT SCIENCES CORPORATION	-20.45%	10.82B
IOVANCE BIOTHERAPEUTICS, INC.	+43.17%	3.25B
GUARDANT HEALTH, INC.	-35.86%	2.11B
BGI GENOMICS CO., LTD.	-17.21%	2.08B
VERACYTE, INC.	-29.81%	1.48B
MARAVAI LIFESCIENCES HOLDINGS, INC.	+17.56%	1.02B
SEEGENE, INC.	-4.37%	733M
CAREDX, INC	-37.00%	391M
ADAPTIVE BIOTECHNOLOGIES CORPORATION	-46.94%	377M

Bio Diagnostics & Testing